Trifiletti Daniel M, Lee Cheng-Chia, Kano Hideyuki, Cohen Jonathan, Janopaul-Naylor James, Alonso-Basanta Michelle, Lee John Y K, Simonova Gabriela, Liscak Roman, Wolf Amparo, Kvint Svetlana, Grills Inga S, Johnson Matthew, Liu Kang-Du, Lin Chung-Jung, Mathieu David, Héroux France, Silva Danilo, Sharma Mayur, Cifarelli Christopher P, Watson Christopher N, Hack Joshua D, Golfinos John G, Kondziolka Douglas, Barnett Gene, Lunsford L Dade, Sheehan Jason P
Department of Radiation Oncology, University of Virginia, Charlottesville, Virginia.
Department of Neurosurgery, Neurological Institute, Taipei Veteran General Hospital, Taipei, Taiwan, People's Republic of China.
Int J Radiat Oncol Biol Phys. 2016 Oct 1;96(2):280-288. doi: 10.1016/j.ijrobp.2016.06.009. Epub 2016 Jun 15.
To pool data across multiple institutions internationally and report on the cumulative experience of brainstem stereotactic radiosurgery (SRS).
Data on patients with brainstem metastases treated with SRS were collected through the International Gamma Knife Research Foundation. Clinical, radiographic, and dosimetric characteristics were compared for factors prognostic for local control (LC) and overall survival (OS) using univariate and multivariate analyses.
Of 547 patients with 596 brainstem metastases treated with SRS, treatment of 7.4% of tumors resulted in severe SRS-induced toxicity (grade ≥3, increased odds with increasing tumor volume, margin dose, and whole-brain irradiation). Local control at 12 months after SRS was 81.8% and was improved with increasing margin dose and maximum dose. Overall survival at 12 months after SRS was 32.7% and impacted by age, gender, number of metastases, tumor histology, and performance score.
Our study provides additional evidence that SRS has become an option for patients with brainstem metastases, with an excellent benefit-to-risk ratio in the hands of experienced clinicians. Prior whole-brain irradiation increases the risk of severe toxicity in brainstem metastasis patients undergoing SRS.
汇总国际上多个机构的数据,并报告脑干立体定向放射外科治疗(SRS)的累积经验。
通过国际伽玛刀研究基金会收集接受SRS治疗的脑干转移瘤患者的数据。使用单变量和多变量分析比较临床、影像学和剂量学特征,以确定局部控制(LC)和总生存期(OS)的预后因素。
在547例接受SRS治疗的596个脑干转移瘤患者中,7.4%的肿瘤治疗导致严重的SRS诱导毒性(≥3级,毒性增加几率与肿瘤体积、边缘剂量和全脑照射增加有关)。SRS后12个月时局部控制率为81.8%,随着边缘剂量和最大剂量增加而改善。SRS后12个月时总生存率为32.7%,受年龄、性别、转移灶数量、肿瘤组织学和性能评分影响。
我们的研究提供了更多证据表明,SRS已成为脑干转移瘤患者的一种选择,在经验丰富的临床医生手中具有良好的风险效益比。既往全脑照射会增加接受SRS治疗的脑干转移瘤患者发生严重毒性的风险。